From: Ontario's Nuclear Advantage <mckennat@cna.ca>


Sent: Tuesday, 2 April 2024 9:05 am

To: Emily Lutz

Subject: Don't forget to register: Ac-225 Spotlight - Nurturing TaT from Production to Patient

Care and Beyond

View this email in your browser



On April 11th, 2024, the Canadian Nuclear Isotope Council (CNIC) and Actineer invite you to attend a scientific webinar, "Ac-225 Spotlight:

Nurturing TaT from Production to Patient Care and Beyond."



This webinar will highlight how innovation and collaboration in the isotope industry are revolutionizing the production of emerging isotopes like actinium-225. This event will profile a new key player in the production of Ac-225, Actineer, the joint venture between Canadian Nuclear Laboratories (CNL) and Isotope Technologies Munich (ITM)

Through discussions of how Actineer is working to pioneer the production of Ac-225 at a commercial scale, this event aims to celebrate Canadian leadership in the production of this rare isotope. Attendees will also hear from experts in nuclear medicine about how Ac-225 and Targeted Alpha Therapy offer significant benefits to patients.

Click here to register

Event Details:

Date: April 11, 2024

Time: 11am-12pm EST

Speakers:

- Carolina de Aguiar Ferreira Assistant Professor of Radiology,
 Pharmacology & Toxicology and Biomedical Engineering at Michigan
 State University
- Mike Sathegke Head of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, South Africa
- Ram Mullur, President of Actineer
- Moderator: Melody Greaves, Manager of Strategic Initiatives, Canadian Nuclear Isotope Council



Copyright © 2022 Ontario's Nuclear Advantage, All rights reserved.

Want to change how you receive these emails?

You can update your preferences or unsubscribe from this list.